Angel Rodriguez
Eli Lilly and Company
11 Papers
16 Citations
Angel Rodriguez is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Type 2 diabetes & Insulin. The author has an hindex of 5, co-authored 11 publications.
Chat about Author
Papers
Early Discontinuation and Restart of Insulin in the Treatment of Type 2 Diabetes Mellitus
Haya Ascher-Svanum,Maureen J. Lage,Magaly Perez-Nieves,Matthew Reaney,Matthew Reaney,Joanne Lorraine,Angel Rodriguez,Michael Treglia +7 more
TL;DR: Among patients with T2DM who were initiated on insulin therapy, early discontinuation of insulin and its subsequent restart were associated with significantly higher acute care costs, which may signal a more complex and challenging subgroup of patients who tend to be less engaged in outpatient care and may have poorer long-term outcomes.
53
Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease
TL;DR: Controversial remains about the use of metformin in moderate CKD and appropriate use of liraglutide and sulfonylureas in advanced CKD, and there is not always good alignment between label recommendations, pharmacokinetic or clinical studies, and guideline recommendations for use of these drugs in CKD.
34
Predictors of Change in Adherence Status from 1 Year to the Next Among Patients with Type 2 Diabetes Mellitus on Oral Antidiabetes Drugs.
Vishal Saundankar,Xiaomei Peng,Haoda Fu,Haya Ascher-Svanum,Angel Rodriguez,Ayad K. Ali,Lane Slabaugh,Peinie Young,Anthony Louder +8 more
TL;DR: Predictive models such as those used in this study can serve as useful and cost-effective tools for payers, helping to identify members that should be targeted for adherence enhancement programs and, ultimately, to improve patients' long-term outcomes.
12
Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus
In Kyung Jeong,Choon Hee Chung,Zhiguang Zhou,Jeong Hee Han,Ran Duan,Diana M. Edralin,Angel Rodriguez +6 more
TL;DR: This analysis evaluated efficacy and safety of insulin lispro low mixture twice daily (breakfast and dinner) versus basal insulin glargine (bedtime) plus prandial insulin l ispro (IGL) once daily before the largest meal in East Asian and Caucasian patients with type 2 diabetes mellitus who failed to reach glycemic targets on basal insulinglargine with metformin and/or pioglitazone.
5
Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial.
Arturo Rojas,Georgina Sposetti,Jorge Luiz Gross,Douglas Eugenio Barbieri,Ran Duan,Bruno Linetzky,Janaina Martins De Lana,Oded Stempa,Angel Rodriguez +8 more
TL;DR: The results suggest that both LM25 and IGL are viable treatment options for insulin intensification in Latin American patients with T2DM with suboptimal glycemic control on basal insulin glargine.